At Aniling, we are committed to bring advances in the Genomics arena to everyday’s health care and disease prevention. We aim to accelerate the access to scientific advances in genomics and epigenomics by developing technologies with the applicability as prime requirement.

Our current work is focused on the improvement of Next Generation Sequencing methods to integrate molecular data into biologically meaning information fulfilling the high quality standards required in clinics.

Our company is a spin-off of the Institute of Predictive and Personalized Medicine of Cancer (IMPPC), with full access to shared resources and facilities of the Can Ruti Campus, that includes the Hospital Germans Trias i Pujol, the Autonomous University of Barcelona and six biomedical research institutes (IMPPC, IGTP, IRSICaixa, IJC, Guttmann Institute and ICO).